Sarepta eyes a different approach to Duchenne: gene therapy – Boston Business Journal
Boston Business Journal |
Sarepta eyes a different approach to Duchenne: gene therapy
Boston Business Journal Sarepta (Nasdaq: SRPT) announced Tuesday that it had reached an agreement with Ohio-based Nationwide Children's Hospital to exclusively license a pre-clinical program that seeks to treat DMD through gene therapy. The company also said it had entered … Sarepta Therapeutics (SRPT) Licenses Galgt2 Gene Therapy Program from Nationwide Children's Hospital Sarepta Enters the Gene Therapy Business For Sarepta, Today's Good News Might Be Just The Beginning |
